Ilay Berke

Ilay Berke

Auto-generated profile, based on publicly available information

Ilay Berke

Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck , Innsbruck

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2024 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
SMSafak Mirioglu
Safak Mirioglu
LDLisa Daniel-Fischer
Lisa Daniel-Fischer
IBIlay Berke
Ilay Berke
SASyed Hasan Ahmad
Syed Hasan Ahmad
IBIngeborg M Bajema
Ingeborg M Bajema
Andreas KronbichlerAndreas Kronbichler
Andreas Kronbichler
The histopathological lesions, minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are entities without immune complex deposits which can cause podocyte injury, thus are frequently grouped under the umbrella of podocytopathies. Whether MCD and FSGS may represent a spectrum of the same disease remains a matter of conjecture. Both frequently require repeated high-dose glucocorticoid therapy with alternative immunosuppressive treatments reserved for relapsing or resistant cases and response rates are variable. There is an unmet need to identify patients who should receive immunosuppressive therapies as opposed to those who would benefit from supportive strategies. Therapeutic trials focusing on MCD are scarce, and the evidence used for the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guideline for the management of glomerular diseases largely stems from observational and pediatric trials. In FSGS, the differentiation between primary forms and those with underlying genetic variants or secondary forms further complicates trial design. This article provides a perspective of the Immunonephrology Working Group (IWG) of the European Renal Association (ERA) and discusses the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases focusing on the management of MCD and primary forms of FSGS in the context of recently published evidence, with a special emphasis on the role of rituximab, cyclophosphamide, supportive treatment options and ongoing clinical trials in the field.

22 May 2023 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
MWMartin Windpessl
Martin Windpessl
MKMyrto Kostopoulou
Myrto Kostopoulou
Richard ConwayRichard Conway
Richard Conway
IBIlay Berke
Ilay Berke
ABAnnette Bruchfeld
Annette Bruchfeld
Andreas KronbichlerAndreas Kronbichler
Andreas Kronbichler
The Coronavirus Disease 2019 (COVID-19) pandemic revealed that our understanding of infectious complications and strategies to mitigate severe infections in patients with glomerular diseases is limited. Beyond COVID-19, there are several infections which specifically impact care of patients receiving immunosuppressive measures. This review will provide an overview of six different infectious complications frequently encountered in patients with glomerular diseases, and will focus on recent achievements in terms of vaccine developments and understanding of the use of specific antimicrobial prophylaxis. These include influenza virus, Streptococcus pneumoniae, reactivation of a chronic or past infection with hepatitis B virus (HBV) in cases receiving B-cell depletion, reactivation of cytomegalovirus (CMV), and cases of Pneumocystis jirovecii pneumonia (PJP) in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Varicella zoster virus (VZV) infections are particularly frequent in patients with systemic lupus erythematosus (SLE) and an inactivated vaccine is available to be used as alternative to the attenuated vaccine in patients receiving immunosuppressants. As with COVID-19 vaccines, vaccine responses are generally impaired in older patients, and after recent administration of B-cell depleting agents, high doses of mycophenolate mofetil and other immunosuppressants. Strategies to curb infectious complications are manifold and will be outlined in this review.

10 April 2025 in Clinical Kidney Journal
Verified
Journal Article
Open access
AMAhmet Murt
Ahmet Murt
IBIlay Berke
Ilay Berke
ABAnnette Bruchfeld
Annette Bruchfeld
FCFernando Caravaca-Fontán
Fernando Caravaca-Fontán
JFJürgen Floege
Jürgen Floege
AKAndreas Kronbichler
Andreas Kronbichler
Glomerular diseases may occur secondary to malignancies. Age-specific cancer screening is recommended for patients with glomerular diseases and may be extended based on the specific risk associated with the detected histopathologic pattern. Membranous nephropathy is the prototype of cancer-associated glomerulonephritis, with 10% of cases presenting with malignancy within a year from diagnosis. Among antigens that are expressed in patients with membranous nephropathy thrombospondin type 1 domain-containing 7A and neural epidermal growth factor-like-1 are often reported in patients with underlying malignancies. However, the risk of having a concurrent malignancy does not exceed 25%–30% when these antigens are expressed. While less frequent in other glomerulonephritides, co-occurrence of malignancy is reported in a substantial proportion of glomerular diseases including IgA nephropathy, podocytopathies with prominent podocyte foot process effacement such as minimal change disease as glomerular lesion pattern, amyloidosis, C3 glomerulopathy, monoclonal immunoglobulin deposition disease, or immune-complex-mediated glomerulonephritis. Treatment of malignancy-associated glomerulonephritis is usually directed toward treatment of the underlying malignancy with combinations of surgery, chemotherapy, and/or radiotherapy. Moreover, relapse of the malignancy may result in recurrence of glomerulonephritis. Refractoriness of glomerulonephritis to initial therapy may be due to an occult primary malignancy that was not diagnosed during initial cancer screening. In such a scenario a step-up diagnostic approach is recommended. In addition, re-screening may be sensible for relapsing patients who carry higher risks for cancer including patients of older age and those with a smoking history. This review focuses on the description of malignancies in the context of glomerular diseases and provides practical guidance on screening.

22 March 2023 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
IMIlay Berke Mentese
Ilay Berke Mentese
AKAndreas Kronbichler
Andreas Kronbichler
The human kidney possesses progenitor cells in the glomerular and tubular compartments of the nephron, capable of self-renewal, proliferation and differentiation. They maintain daily homeostasis and are involved in endogenous regenerative processes following injury [ 1]. However, defective or abnormal regenerative responses of these cells can result in pathological conditions [ 2].

5 October 2024 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
IBIlay Berke
Ilay Berke
DADilek Barutcu Atas
Dilek Barutcu Atas
MTMurat Tugcu
Murat Tugcu
HAHakki Arikan
Hakki Arikan
AVArzu Velioglu
Arzu Velioglu
EAEbru Asicioglu
Ebru Asicioglu

18 June 2021 in Progress in Transplantation
Verified
Journal Article
Closed access
PDF file
IMIlay Berke Mentese
Ilay Berke Mentese
AVArzu Velioglu
Arzu Velioglu
BABasar Aykent
Basar Aykent
DGDeniz Sevindik Gunay
Deniz Sevindik Gunay
HAHakki Arikan
Hakki Arikan
STSerhan Tuglular
Serhan Tuglular